Breast Cancer Drugs Need Survival Benefit for Full Approval, Cmtte. Says
Executive Summary
Time to progression is a sufficiently reliable surrogate endpoint for accelerated approval of drug therapies for breast cancer, but not for unqualified regular approval of first-line therapies, FDA's Oncologic Drugs Advisory Committee decided unanimously June 7.
You may also be interested in...
Progression-Free Survival Represents Clinical Benefit, But How Much? – ODAC
While the Oncologic Drugs Advisory Committee generally endorses the idea that progression-free survival can support full approval of first-line therapies in metastatic breast cancer, the panel left FDA with the challenge of qualifying how PFS represents clinical benefit and determining the measure's meaningfulness for regulatory purposes
Progression-Free Survival Represents Clinical Benefit, But How Much? – ODAC
While the Oncologic Drugs Advisory Committee generally endorses the idea that progression-free survival can support full approval of first-line therapies in metastatic breast cancer, the panel left FDA with the challenge of qualifying how PFS represents clinical benefit and determining the measure's meaningfulness for regulatory purposes
Eloxatine Progression-Free Survival Data Not Enough For Colorectal Use
Studies showing an overall survival advantage for Sanofi-Synthelabo's Eloxatine over 5-FU-based chemotherapy would be needed for approval of the agent as first-line therapy for colorectal cancer, FDA's Oncologic Drugs Advisory Committee found March 16.